ArticleScientific reports2025
Increased depth of pancreas incisure on computed tomography as an independent predictor for T2DM.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We aim to identify CT-based biomarkers in the pancreas for predicting both the presence and prognosis of T2DM. Between January and December 2021, a population of 2246 subjects undertaken health-check were recruited. Between January 2023 and June 2024, another 244 hospitalized patients with T2DM were recruited. Depth of pancreas incisure (DPI), CT attenuation, and thickness were measured using an unenhanced CT scan. Compared to individuals without T2DM, DPI was significantly increased in subjects with T2DM, regardless of whether they were of normal weight or obese. After adjusting for age, sex, BMI, waist circumference, lipid, liver function, and hepatic fat content, DPI remained independently associated with the presence of T2DM. However, no significant difference in DPI was observed between T2DM patients without insulin deficiency [Fasting C-peptide (FCP) ≥ 0.6 ng/ml] and those with absolute insulin deficiency (FCP < 0.6 ng/ml). DPI was not associated with the presence of absolute insulin deficiency; conversely, reduced pancreatic thickness was independently associated with this condition. Additionally, our findings did not reveal any significant association between pancreatic fat content and T2DM. Increased DPI may serve as a potential biomarker for predicting the risk of T2DM, whereas reduced pancreatic size may indicate a poorer prognosis for this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.